What should be included when comparing the total monthly cost of GLP-1 care with Medicare?

Total monthly GLP-1 cost on Medicare includes your Part D premium, deductible, copay/coinsurance, and any costs incurred during the coverage gap.

Medicare Part D Coverage for GLP-1 Medications

Medicare Part D plans may cover GLP-1 receptor agonists like Ozempic or Mounjaro, but typically only when prescribed for their FDA-approved indication of type 2 diabetes. Each Part D plan has its own formulary, or list of covered drugs, which can vary.

Crucially, federal law currently excludes drugs used for chronic weight management from Medicare Part D coverage. This means brand-name drugs like Wegovy or Zepbound, which are indicated for weight loss, are generally not covered by Medicare plans.

To confirm coverage, you must check your specific Part D plan's formulary. If a GLP-1 is covered for your condition (e.g., type 2 diabetes), you will still have out-of-pocket costs determined by your plan's structure, including deductibles, copayments, and the coverage gap.

Calculating Out-of-Pocket Costs for Covered Brand-Name Drugs

Your total cost begins with your plan's annual deductible. For 2024, the standard Part D deductible is up to $545. You must pay this amount out-of-pocket before your plan's coverage begins.

After the deductible, you enter the initial coverage phase and pay a copayment or coinsurance for each prescription. This continues until the total cost of your drugs (what you and your plan pay) reaches $5,030 in 2024.

Next, you enter the coverage gap, or "donut hole." Here, you are responsible for 25% of the cost of your brand-name drugs until your total out-of-pocket spending reaches $8,000. With GLP-1 list prices often exceeding $1,000 per month, many patients enter the gap quickly.

Once your out-of-pocket spending reaches $8,000, you enter catastrophic coverage. For the remainder of the year, you will have no further out-of-pocket costs for covered Part D drugs.

Limitations of Manufacturer Savings Programs

Pharmaceutical manufacturers often offer savings cards or copay assistance programs to reduce the cost of brand-name medications. These programs can significantly lower out-of-pocket expenses for patients with commercial insurance.

However, patients enrolled in government-funded healthcare programs, including Medicare, Medicaid, or TRICARE, are legally prohibited from using these manufacturer savings programs. This means Medicare beneficiaries cannot use a Wegovy or Ozempic copay card.

This restriction is in place to prevent violations of anti-kickback statutes. Therefore, Medicare patients must budget for the full out-of-pocket costs dictated by their Part D plan's structure without the help of these common savings tools.

Comparing with All-Inclusive Telehealth Programs

Physician-supervised telehealth programs offer an alternative model. These programs often provide access to compounded medications, including semaglutide or tirzepatide, as part of a comprehensive care plan for a flat monthly fee.

It is essential to understand that compounded medications are prepared by licensed U.S. pharmacies but are not FDA-approved. They are prescribed by a physician based on an individual's specific clinical needs.

When comparing costs, consider that a program like GOAL.MD includes the physician consultations, medication, supplies, and shipping in one predictable monthly price. This contrasts with the variable costs of Part D, which include deductibles, tiered copays, and potential high costs in the coverage gap.

This all-inclusive structure can simplify budgeting, particularly for uses like [weight management](/weight-loss) that are not covered by Medicare, by eliminating the guesswork of pharmacy pricing and insurance formularies.

Bottom Line

When calculating the total monthly cost of GLP-1 care with Medicare, you must account for your Part D plan's premium, deductible, and cost-sharing until you reach the catastrophic coverage limit. Coverage is typically restricted to type 2 diabetes, excluding weight loss.

Manufacturer savings cards are not an option for Medicare patients. The final cost for a covered brand-name GLP-1 depends on your progression through the Part D payment stages: deductible, initial coverage, coverage gap, and catastrophic coverage.

Alternative physician-supervised programs offer a flat-fee model that includes the provider care, medication (such as compounded, non-FDA-approved semaglutide), and support, providing a predictable monthly cost instead of a variable one. This may be a considered option for indications not covered by Medicare.

This information is for educational purposes only and does not constitute medical advice.

Generated from GOAL.MD's physician-reviewed source library. This page has not received its own physician review. Physician-supervised telehealth. More at goal.md/answers.